Global Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
13,385.56
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 13,385.56 |
 CAGR |
% |
| Major Markets Players |
>全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场，按诊断（影像学检查和胰腺功能测试）、治疗（营养管理、胰酶替代疗法(PERT)、药物类型（仿制药和品牌药）、最终用户（医院、专科诊所、家庭护理、诊断中心、研究和学术机构等）、分销渠道（直接招标、零售药店、第三方分销商等）划分 - 行业趋势和预测到 2030 年。
外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分析和见解
全球对先进诊断技术的认识不断提高，增强了市场需求。为获得更好的医疗服务而增加的医疗支出也促进了市场的增长。在这一关键时期，主要市场参与者专注于各种服务的推出和批准。此外，工艺和技术的改进也促进了对外分泌性胰腺功能不全 (EPI) 治疗和诊断的需求增加。
由于市场参与者的增加和先进服务的可用性，全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场预计将在预测年内增长。与此同时，制造商正致力于开发活动，以向市场推出新服务。先进医疗技术的不断发展进一步推动了市场的增长。然而，严格的法规阻碍了外分泌性胰腺功能不全 (EPI) 治疗和诊断行业的发展，与胰腺酶替代疗法 (PERT) 相关的副作用和宗教障碍等困难可能会阻碍预测期内全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场的增长。
预计医疗保健支出的增加将为市场带来机遇。然而，EPI 诊断和治疗的高成本可能会对市场增长构成挑战。
Data Bridge Market Research 分析称，全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场预计到 2030 年将达到 133.8556 亿美元的价值，预测期内的复合年增长率为 7.2%。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）和定价（美元） |
|
涵盖的领域 |
诊断（影像学检查和胰腺功能检查）、治疗（营养管理、胰酶替代疗法 (PERT)、药物类型（仿制药和品牌药）、最终用户（医院、专科诊所、家庭护理、诊断中心、研究和学术机构等）、分销渠道（直接招标、零售药店、第三方分销商等） |
|
覆盖国家 |
美国、加拿大、墨西哥、德国、法国、英国、意大利、西班牙、荷兰、俄罗斯、瑞士、土耳其、比利时、丹麦、芬兰、挪威、瑞典、波兰、欧洲其他地区、中国、日本、印度、韩国、澳大利亚、新西兰、新加坡、泰国、马来西亚、印度尼西亚、菲律宾、越南、台湾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、巴林、科威特、卡塔尔、阿曼、阿联酋、埃及、以色列、中东和非洲其他地区 |
|
涵盖的市场参与者 |
EagleBio、AbbVie.、Nordmark Arzneimittel GmbH & Co.、Digestive Care, Inc.、Cilian AG、Alcresta Therapeutics, Inc.、ChiRhoClin、Abbott、Bioserv Diagnostics、Laboratory Corporation of America、Organon 集团公司 Metagenics LLC、Janssen、Nestlé.、VIVUS LLC. 和 ScheBo Biotech AG 等 |
市场定义
外分泌性胰腺功能不全 (EPI) 是一种疾病，指胰腺无法产生足够的消化酶来消化肠道中的脂肪、蛋白质和碳水化合物。EPI 可由多种疾病引起，例如慢性胰腺炎、囊性纤维化和胰腺癌。EPI 的治疗方法包括使用胰酶替代疗法 (PERT)，该疗法可提供胰腺无法产生的必要消化酶。PERT 通常与正餐和零食一起服用，以帮助分解食物并正确吸收营养；目前有多种 PERT 产品可供选择，例如胰腺脂肪酶、胰酶和脂肪酶。
EPI 的诊断可能涉及血液检查（测量血液中的消化酶水平）、粪便弹性蛋白酶检查（检查粪便中的胰腺弹性蛋白酶水平）以及影像学检查（例如 CT 扫描、MRI 或内窥镜超声检查）以观察胰腺并检测任何异常。此外，呼吸测试可以测量呼吸中的氢气和甲烷水平，以指示 EPI。
全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场动态
本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：
驱动程序
- 慢性胰腺炎和囊性纤维化导致胰腺外分泌功能不全（EPI）患病率不断上升
外分泌性胰腺功能不全 (EPI) 是由于胰腺无法产生足够的消化酶来帮助消化和吸收营养而引起的一种疾病。慢性胰腺炎是成人 EPI 的主要原因。胰腺炎会导致胰腺发炎和肿胀。随着时间的推移，它会损害产生消化酶的胰腺细胞。同样，囊性纤维化是儿童 EPI 的主要原因之一。它是从父母那里遗传的，会导致肺部积聚浓稠的粘液，造成呼吸困难。粘液也会积聚在胰腺中，阻止消化酶到达小肠。患有 EPI 的人无法从食物中吸收足够的脂肪、蛋白质和碳水化合物，这被称为吸收不良。
因此，慢性胰腺炎和囊性纤维化导致的 EPI 患病率不断上升将推动预测期内市场的增长。
- EPI 诊断和治疗技术不断进步
目前，关于最佳诊断方法尚未达成共识，专家们指出，现有诊断测试不可靠且不具特异性。现有的 EPI 诊断测试包括粪便脂肪定量、粪便弹性蛋白酶-1 测试和 C-混合甘油三酯呼气试验。开发一种机器学习模型，识别商业医疗索赔数据库中可能患有 EPI 但未确诊的患者，是推进 EPI 诊断和治疗框架的最新目标之一。
因此，EPI 诊断和治疗技术的不断进步将推动预测期内市场的增长。
克制
- 严格的法规阻碍了胰腺外分泌功能不全 (EPI) 治疗和诊断行业的发展
随着老龄人口的增长和多种可通过早期诊断预防的慢性疾病，全球范围内治疗 EPI 疾病的疗法和药物的使用正在迅速增加。同时，市场上 EPI 疾病产品制造商的参与者必须遵守某些法规，以获得上级部门的批准才能将产品推向市场。必须遵守这些严格的指导方针，这是所有步骤中最困难的任务之一。美国食品药品监督管理局 (FDA) 负责监管美国，欧盟 (EU) 负责监管欧洲。然而，亚太地区和欧洲、中东和非洲地区（包括印度、俄罗斯、中国、韩国、新加坡、香港和澳大利亚）的隐私政策和法规正在迅速发展。包括美国食品药品监督管理局 (FDA) 在内的一些药品监管机构已指示制造商在销售其产品之前获得监管部门的批准，因为产品可能存在不良影响且效果不佳。这些严格的 FDA 法规使得胰腺脂肪酶产品的批准变得困难。
因此，从上述情况可以得出结论，严格的规定可能会抑制预测期内外分泌治疗不足治疗和诊断市场的增长。
机会
-
胰腺疾病及相关疾病的患病率不断上升
EPI 是胰腺疾病（如癌症、囊性纤维化和慢性胰腺炎）的一个显著副作用。这些疾病会损害胰腺，削弱其产生消化酶的能力并导致 EPI。全球范围内胰腺疾病和相关疾病的患病率不断上升，推动了对 EPI 治疗和诊断的需求。这些疾病会对胰腺造成损害，导致产生消化酶的能力下降，从而导致 EPI。囊性纤维化对胰腺的损害使其成为另一种可能导致 EPI 的疾病。被称为囊性纤维化的遗传性疾病会影响生殖系统、消化系统和呼吸系统。囊性纤维化在白种人中更为常见，尤其是那些具有北欧血统的人，在世界范围内更常见。随着这些疾病的发病率不断上升，对 EPI 治疗和诊断的需求预计也会增长。这为制药公司和制造商开发新的有效 EPI 治疗方法和诊断测试提供了重要机会。
因此，胰腺疾病和相关疾病的患病率不断上升有望为市场增长带来机遇。
挑战
- EPI 诊断和治疗相关费用高昂
由于病情复杂，需要进行专门的检查，因此 EPI 的诊断费用昂贵。粪便弹性蛋白酶检测、促胰液素刺激胰腺功能检测以及磁共振成像 (MRI) 和内镜超声检查 (EUS) 等影像学检查是 EPI 最常用的诊断程序。这些检查可能价格昂贵，而且并非所有医疗专业人员都能获得进行这些检查所需的工具和培训。识别 EPI 的高昂费用还可能延误诊断，这可能会加剧症状并随着时间的推移增加医疗成本。未经治疗的 EPI 可能导致患者持续出现消化问题、营养吸收不良和体重减轻，所有这些都会增加医疗费用和困难。
因此，预计与 EPI 诊断和治疗相关的高成本将成为市场增长的挑战。
最新动态
- 2021 年 8 月，AzurRx 宣布已致力于开发酵母衍生的脂肪酶 MS1819，该酶经过改造，与目前的治疗方法相比具有更优异的酶活性。
- 2023 年 2 月，Codexis, Inc. 和雀巢健康科学宣布了第一阶段试验的中期结果，该试验研究了 CDX-7108 的安全性、耐受性、药代动力学 (PK) 和药效学。一种名为 CDX-7108 的脂肪酶变体是专门为解决当前胰酶替代疗法 (PERT) 的缺点而创建的。这有助于该公司营销该产品。
全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场范围
全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分为五个显著的细分市场，例如诊断、治疗、药物类型、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
诊断
- 影像学检查
- 胰腺功能检查
根据诊断，全球外分泌胰腺功能不全 (EPI) 治疗和诊断市场分为影像学测试和胰腺功能测试。
治疗
- 营养管理
- 胰酶替代疗法（PERT）
根据治疗，全球外分泌胰腺功能不全 (EPI) 治疗和诊断市场分为营养管理和胰酶替代疗法 (PERT)。
药物类型
- 通用的
- 品牌
根据药物类型，全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分为仿制药和品牌药。
最终用户
- 医院
- 专科诊所
- 家庭护理
- 诊断中心
- 研究与学术机构
- 其他的
根据最终用户，全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分为医院、专科诊所、家庭护理、诊断中心、研究和学术机构等。
分销渠道
- 直接招标
- 零售药店
- 第三方分销商
- 其他的
根据分销渠道，全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分为直接招标、零售药店、第三方分销商和其他。
全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场区域分析/见解
全球外分泌性胰腺功能不全 (EPI) 治疗和诊断市场分为诊断、治疗、药物类型、最终用户和分销渠道五个显著部分。
The countries covered in this market report U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Finland, Norway, Sweden, Poland, and Rest of Europe, China, Japan, India, South Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, Bahrain, Kuwait, Qatar, Oman, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
North America is dominating due to the presence of key market players in the largest consumer market with high GDP. The U.S is expected to grow due to the rise in technological advancement in the market.
North America is dominating the market due to the increasing investment in healthcare is expected to boost the market growth. The U.S. dominates the North America region due to the strong presence of key players. Germany dominates Europe due to the increasing demand from emerging markets and expansion. Japan dominates the Asia-Pacific region due to increasing customer inclinations towards advanced technological processes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share Analysis
Global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market competitive landscape provide details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global nurse call systems market.
Some of the major players operating in the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are EagleBio, AbbVie., Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, Organon group of companies Metagenics LLC, Janssen, Nestlé., VIVUS LLC., and ScheBo Biotech AG among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER ANALYSIS
5 INDUSTRY INSIGHTS
6 REGULATORY FRAMEWORK
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS
7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI
7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS
7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR
7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)
7.3 OPPORTUNITIES
7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION
7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI
7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE
7.4 CHALLENGES
7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT
7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS
8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)
8.2.1 BY ENZYME
8.2.1.1 LIPASE
8.2.1.2 PROTEASE
8.2.1.3 AMYLASE
8.2.2 BY ROUTE OF ADMINISTRATION
8.2.2.1 ORAL
8.2.2.1.1 CAPSULES
8.2.2.1.2 TABLETS
8.2.2.1.3 POWDER
8.2.2.2 INTRAVENOUS
8.3 NUTRITIONAL MANAGEMENT
8.3.1 VITAMIN D
8.3.2 VITAMIN E
8.3.3 VITAMIN A
8.3.4 VITAMIN K
8.3.5 OTHERS
9 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PANCREATIC FUNCTION TEST
9.2.1 STOOL
9.2.1.1 FECAL ELASTASE TEST
9.2.1.2 FECAL FAT TEST
9.2.2 SECRETIN PANCREATIC FUNCTION TEST
9.2.3 BLOOD TESTS
9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST
9.2.5 FASTING PLASMA GLUCOSE TEST
9.3 IMAGING TEST
9.3.1 CT SCANNING
9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI)
9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS)
9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY
10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.2.1 CREON
10.2.2 ZENPEP
10.2.3 PANCREAZE
10.2.4 NUTRIZYM
10.2.5 PANCREASE MT
10.2.6 PANCREX
10.2.7 COTAZYM
10.2.8 ULTERSA
10.2.9 VIOKACE
10.2.10 PERTZYE
10.2.11 OTHERS
10.3 GENERIC
11 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PRIVATE
11.2.2 PUBLIC
11.3 SPECIALTY CLINICS
11.4 DIAGNOSTIC CENTER
11.5 HOMECARE
11.6 RESEARCH AND ACADEMIC INSTITUTES
11.7 OTHERS
12 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL PHARMACY
12.4 THIRD PARTY DISTRIBUTORS
12.5 OTHERS
13 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 SPAIN
13.3.6 RUSSIA
13.3.7 TURKEY
13.3.8 BELGIUM
13.3.9 DENMARK
13.3.10 NETHERLANDS
13.3.11 SWITZERLAND
13.3.12 SWEDEN
13.3.13 POLAND
13.3.14 NORWAY
13.3.15 FINLAND
13.3.16 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 JAPAN
13.4.2 CHINA
13.4.3 SOUTH KOREA
13.4.4 INDIA
13.4.5 AUSTRALIA
13.4.6 NEW ZEALAND
13.4.7 SINGAPORE
13.4.8 THAILAND
13.4.9 MALAYSIA
13.4.10 VIETNAM
13.4.11 TAIWAN
13.4.12 INDONESIA
13.4.13 PHILIPPINES
13.4.14 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 SAUDI ARABIA
13.6.3 BAHRAIN
13.6.4 U.A.E.
13.6.5 KUWAIT
13.6.6 OMAN
13.6.7 QATAR
13.6.8 EGYPT
13.6.9 ISRAEL
13.6.10 REST OF MIDDLE EAST AND AFRICA
14 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBVIE INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 NESTLE
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 JANSSEN GLOBAL SERVICES, LLC
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 ALCRESTA THERAPEUTICS, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 COMPANY SHARE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOSERV DIAGNOSTICS GMBH
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CILIAN AG
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 CHIRHOCLIN
16.9.1 COMPANY SNAPSHOT
16.9.2 COMPANY SHARE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 DIGESTIVE CARE, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 EAGLEBIO
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 METAGENICS LLC
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 NORDMARK
16.13.1 COMPANY SNAPSHOT
16.13.2 COMPANY SHARE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 ORGANON GROUP OF COMPANIES.
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SCHEBO BIOTECH AG
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 VIVUS LLC
16.16.1 COMPANY SNAPSHOT
16.16.2 COMPANY SHARE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 2 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ENZYME, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL ORAL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL STOOL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL GENERIC IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL SPECIALTY CLINICS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL DIAGNOSTIC CENTER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL HOMECARE IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL RESRACH AND ACADEMIC INSTITUTES IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL DIRECT TENDER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL RETAIL PHARMACY IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL THIRD PARTY DISTRIBUTORS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS IS EXPECTED TO DRIVE THE FIGURE 10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET
FIGURE 16 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2022
FIGURE 17 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 18 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 19 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2022
FIGURE 21 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 22 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 23 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 24 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2022
FIGURE 25 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 26 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 27 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 29 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 30 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 31 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 33 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 34 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 35 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 37 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2022)
FIGURE 38 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2023 & 2030)
FIGURE 39 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2022 & 2030)
FIGURE 40 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 41 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 42 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 43 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 44 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 45 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 46 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 47 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 48 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 49 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 50 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 51 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 52 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 53 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 56 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 57 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 58 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 59 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 60 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 61 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 62 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 63 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 64 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 65 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030)
FIGURE 66 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 67 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 68 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
FIGURE 69 AISA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICSMARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
